Simultaneous determination of Pyragrel, a novel anti-thrombotic agent, and its two primary metabolites in plasma by HPLC-MS/MS

被引:4
作者
Yang, Guoping [1 ]
Pei, Qi [3 ]
Fu, Chengxiao [1 ]
Huang, Jie [1 ]
Chen, Jun [1 ]
Yang, Shuang [1 ]
Xiang, Yuxia [1 ]
Wang, Jing [3 ]
Tan, Hongyi [1 ,3 ]
Liu, Xiaolei [2 ]
机构
[1] Cent S Univ, Xiangya Hosp 3, Ctr Clin Pharmacol, Changsha 410013, Hunan, Peoples R China
[2] Univ Cincinnati, Coll Med, Dept Internal Med, Cincinnati, OH 45267 USA
[3] Cent S Univ, Xiangya Hosp 3, Dept Pharm, Changsha 410013, Hunan, Peoples R China
关键词
Pyragrel; LC-MS/MS; Human plasma; Pharmacokinetics; THROMBOXANE; AGGREGATION; ISCHEMIA; OZAGREL;
D O I
10.1016/j.jpba.2018.04.010
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Pyragrel is a novel thromboxane A2-synthetase inhibitor for the treatment of cerebral infarction, and it is currently being investigated in phase I clinical trials. This paper reports the first reliable LC-MS/MS method for the simultaneous determination of Pyragrel and its two main metabolites, M1 and M2, in human plasma. All analytes were extracted from human serum using liquid-phase extraction and separated on a Zorbax EcLipse XDB C18 column using isocratic elution with a mobile phase composed of methanol, water and formic acid (65:35:0.1, v/v/v). Determination of the analytes was achieved by tandem-mass spectrometry with positive electrospray ionization. The multiple reaction monitoring transitions under positive electrospray ionization were performed at m/z 329.0 -> m/z 135.9 for Pyragrel, m/z 303.1 -> m/z 135.0 for Ml, m/z 331.2 -> m/z 135.0 for M2, and 482.2 -> m/z 258.0 for IS, respectively. The following parameters were validated: specificity, recovery, matrix effects, carry-over, linearity, sample stability under a variety of storage and handling conditions, and stock solution stability. The validated method has been successfully applied to an initial pharmacokinetic study in healthy volunteers following intravenous administrations of 60 mg of Pyragrel, and this method will facilitate further studies involving more comprehensive identification of the metabolic profile of Pyragrel and the appropriate dosage regimen. (C) 2018 Elsevier B.V. All rights reserved.
引用
收藏
页码:199 / 205
页数:7
相关论文
共 8 条
[1]   THROMBOXANE, PROSTACYCLIN, AND LEUKOTRIENES IN CEREBRAL-ISCHEMIA [J].
CHEN, ST ;
HSU, CY ;
HOGAN, EL ;
HALUSHKA, PV ;
LINET, OI ;
YATSU, FM .
NEUROLOGY, 1986, 36 (04) :466-470
[2]   MC-002 exhibits positive effects against platelets aggregation and endothelial dysfunction through thromboxane A2 inhibition [J].
Fang, Weirong ;
Wei, Jie ;
Han, Dan ;
Chen, Xi ;
He, Guangwei ;
Wu, Qiang ;
Chu, Shaoxing ;
Li, Yunman .
THROMBOSIS RESEARCH, 2014, 133 (04) :610-615
[3]   A Selective Thromboxane A2 (TXA2) Synthase Inhibitor, Ozagrel, Attenuates Lung Injury and Decreases Monocyte Chemoattractant Protein-1 and Interleukin-8 mRNA Expression in Oleic Acid-Induced Lung Injury in Guinea Pigs [J].
Ishitsuka, Yoichi ;
Moriuchi, Hiroshi ;
Isohama, Yoichiro ;
Tokunaga, Hidehiro ;
Hatamoto, Keita ;
Kurita, Sumika ;
Irikura, Mitsuru ;
Iyama, Ken-ichi ;
Irie, Tetsumi .
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2009, 111 (02) :211-215
[4]   ACCUMULATION OF ARACHIDONIC-ACID CYCLOOXYGENASE AND LIPOXYGENASE PRODUCTS IN RAT-BRAIN DURING ISCHEMIA AND REPERFUSION - EFFECTS OF TREATMENT WITH GM1-LACTONE [J].
PETRONI, A ;
BERTAZZO, A ;
SARTI, S ;
GALLI, C .
JOURNAL OF NEUROCHEMISTRY, 1989, 53 (03) :747-752
[5]   Human thromboxane synthase: comparative modeling and docking evaluation with the competitive inhibitors Dazoxiben and Ozagrel [J].
Sathler, Plino Cunha ;
Santana, Marcos ;
Lourenco, Andre Luiz ;
Rodrigues, Carlos Rangel ;
Abreu, Paula ;
Cabral, Lucio Mendes ;
Castro, Helena Carla .
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2014, 29 (04) :527-531
[6]   Bioanalytical method validation: notable points in the 2009 draft EMA Guideline and differences with the 2001 FDA Guidance [J].
Smith, Graeme .
BIOANALYSIS, 2010, 2 (05) :929-935
[7]  
Xie Di, 2015, Yaoxue Xuebao, V50, P326
[8]  
Zhao X, 2017, Molecules, V22